Local and systemic oxidative stress and glucocorticoid receptor levels in chronic obstructive pulmonary disease patients

Canadian Respiratory Journal

Volumn 20, Issue 1, 2013, Pages 35-41

  Zeng, Mian ^a   Li, Yue ^a   Jiang, Yujie ^a   Lu, Guifang ^a   Huang, Xiaomei ^a   Guan, Kaipan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chronic obstructive pulmonary disease; Oxidants; Plasma; Sputum

Indexed keywords

GLUCOCORTICOID RECEPTOR; GLUTATHIONE; GLUTATHIONE PEROXIDASE; LIPID PEROXIDE; MALONALDEHYDE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME ACTIVITY; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SMOKING; SPUTUM LEVEL;

EID: 84876261524     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/985382     Document Type: Article

References (27)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of COPD: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
2. Harju TH, Peltoniemi MJ, Rytila PH, et al. Glutathione S-transferase omega in the lung and sputum supernatants of COPD patients. Respir Res 2007;8:48.
3. Rytila P, Rehn T, Ilumets H, et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res 2006;7:69.
4. Kinnula VL, Ilumets H, Myllarniemi M, et al. 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur Respir J 2007;29:51-5.
5. Altuntas E, Turgut T, Ilhan N, et al. The levels of oxidant and antioxidant in patients with COPD. Tuberk Toraks 2003;51:373-9.
6. Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 2005;29:23-32.
7. Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI3Kd restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 2009;179:542-8.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl 1):S1-S266.
9. The Criteria Committee of the New York Heart Association. Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis, 6th edn. Boston: Little Brown; 1964.
10. Hector A, Jonas F, Kappler M, et al. Novel method to process cystic fibrosis sputum for determination of oxidative state. Respiration 2010;80:393-400.
11. Gerald RC, Kendall AS, Allan M. Glucocorticoid receptors and sensitivity of isolated human leukemia and lymphoma cells. Cancer Res 1978;38:4268-72.
12. Wasowicz W, Neve J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acidreactive substances in serum: Importance of extraction pH and influence of sample preservation and storage. Clin Chem 1993;39:2522-6.
13. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-69.
14. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497-500.
15. Zeng M, Wu JF, Xie CM, et al. Safety of sputum induction in subjects with acute exacerbations of chronic obstructive pulmonary disease. Chinese J Tuberculos Respir Dis 2005;28:238-41.
16. Zeng M, Wen Y, Liu LY, et al. Role of TNF-a, sTNF-R55 and sTNF-R75 in inflammation of acute exacerbations of chronic obstructive pulmonary disease. Respiration 2009;78:399-403.
17. Beeh KM, Beier J, Kornmann O, et al. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003;123:778-83.
18. Brightling CE, Monterio W, Green RH, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: Safety and repeatability. Respir Med 2001;95:999-1002.
19. Boorsma M, Lutter R, van de Pol MA, et al. Repeatability of inflammatory parameters in induced sputum of COPD patients. COPD 2007;4:321-9.
20. Beier J, Beeh KM, Kornmann O, et al. Stability of glutathione in induced sputum: Impact of freezing. Respiration 2003;70:523-7.
21. Grootendorst DC, Sont JK, Willems LN, et al. Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy 1997;27:769-79.
22. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006;28:219-42.
23. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002;15:35-50.
24. Matthews JG, Ito K, Barnes PJ, et al. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. J Allergy Clin Immunol 2004;113:1100-8.
25. Loke TK, Mallett KH, Ratoff J, et al. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J Allergy Clin Immunol 2006;118:368-75.
26. Corrigan CJ, Loke TK. Clinical and molecular aspects of glucocorticoid resistant asthma. Ther Clin Risk Manag 2007;3:771-87.
27. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor a in refractory asthma. N Engl J Med 2006;354:697-708.